NASA’s science budget won’t be a train wreck after all

Congress released a $24.4 billion NASA budget plan as part of conferees' negotiations, effectively reversing a White House proposal that would have slashed NASA science funding by nearly 50%. The conference plan calls for only a 1% cut to NASA science to $7.25 billion for FY2026, halting preliminary closeout planning for active missions, though planned workforce reductions via a 2025 voluntary buyout and other headcount efforts remain in place. Stakeholders including The Planetary Society praised the outcome as substantially better than expected, while noting wasted staff time responding to the initial White House proposal.

Analysis

Market structure: Congress-preserving NASA science funding (~$7.25bn, ~1% cut vs prior FY) keeps procurement flows intact for prime contractors (LMT, NOC, RTX, BA) and satellite suppliers (MAXR, LHX). Small-cap launchers and mission-specific vendors face idiosyncratic risk as discretionary mission selections limp along; expect a 3–10% reallocation of near-term contract awards toward large primes over 12–24 months. Pricing power shifts modestly to primes who have stable backlog and to vertically integrated GEO/EO suppliers that replace smaller mission cancellations.

Risk assessment: Tail risks include a final appropriations reversal or a targeted program cancelation (5–15% probability) that would crater niche suppliers and small-cap launchers. Immediate (days) volatility should be low; short-term (weeks–months) catalyst windows are appropriations votes and NASA mission notifications; long-term (years) risks include workforce reductions causing capacity constraints and higher labor costs, pressuring margins for smaller contractors. Hidden dependency: many small suppliers rely on NASA-funded science grants—cuts cascade into private funding and startup viability.

Trade implications: Favor overweight aerospace & defense equities and select satellite/EO suppliers; underweight speculative commercial-space launchers and space-tourism names. Use relative-value pair trades (long LMT/NOC vs short RKLB/SPCE) and options to express asymmetric upside (buy-call spreads on LMT, long-dated LEAP calls on MAXR). Time entries to capture expected congressional confirmations—establish positions within 2–6 weeks and re-evaluate at the final appropriations vote (~30–60 days).

Contrarian angles: Consensus frames this as a narrow win for NASA; overlooked is structural tightening of skilled labor and program selectivity that can boost long-term margins for primes (historical parallel: post-sequestration consolidation). The market may underprice margin tailwinds for incumbents and overprice growth for small launchers dependent on NASA mission cadence. Key unintended consequence: cancelled science grants may accelerate commercial partnerships, benefiting integrated EO/data-play providers over pure-play launchers.

Key Decisions for Investors

• Establish a 2–3% long position in Lockheed Martin (LMT) and a 1–2% long in Northrop Grumman (NOC), funded by reducing cash, to capture backlog stability and potential margin expansion; target a 6–12 month horizon and trim at +15–25% gains or if appropriations vote fails.
• Allocate 1–2% to Maxar Technologies (MAXR) long via 9–12 month LEAP calls (or buy 2–3% delta OTM calls) to play sustained demand for earth-observation/spacecraft components; exit if MAXR underperforms peers by >10% over 60 days or if NASA cancels >3 major EO contracts.
• Establish a 1% short position in Rocket Lab (RKLB) or 2–3% short exposure to SPCE via CFDs/options to hedge speculative commercial-launch risk; cover within 90 days if RKLB reports a new multi-mission NASA award or SPCE announces material revenue diversification.
• Implement a pair trade: long 2% XAR (aerospace & defense ETF) and short 1–2% of pure-play commercial-space ETFs or names (e.g., SPCE/RKLB) to express relative-strength of primes; rebalance after final appropriations (30–60 days) and close if sector dispersion compresses below 5%.